Combining Pluvicto with radiation therapy for advanced prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of using the drug Pluvicto in conjunction with stereotactic body radiation therapy (SBRT) for patients with locally advanced prostate cancer. Participants will receive a dose of Pluvicto followed by radiation therapy approximately six weeks later, with the possibility of additional doses of Pluvicto. The study seeks to determine if this approach can reduce the risk of cancer recurrence while preserving patients' quality of life, as an alternative to traditional androgen-deprivation therapy. The trial will assess both the safety and oncologic outcomes of this treatment combination.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participant must be ≥ 18 years of age.
* ECOG performance status ≤ 1
* Histologic confirmation of prostate adenocarcinoma of the prostate
* PSMA avid disease on PSMA PET/CT, where the tumor in the prostate has SUVmax ≥ 10.

  * PSMA PET/CT must be obtained within 4 months.
* Need ≥ 1 criteria:

  * Node positive disease on PSMA PET/CT or conventional imaging, as defined by having any of the following:

    * Pelvic nodal disease (cN1) as defined by LN stations that commence at the bifurcation of the common iliac vessels
    * Regional nodal disease (M1a) as defined by LN stations that commence at the bifurcation of the aorta and bifurcation of the proximal inferior vena cava to the common iliac veins.
  * In the absence of nodal metastasis, must have ≥ 2 of the following

    * i. cT3a or cT3b by conventional imaging (MRI) or PSMA PET/CT
    * ii. Grade group ≥ 4
    * iii. PSA ≥ 40 ng/mL
* Adequate organ and marrow function to receive treatment:

  * Hemoglobin \> 10 g/dL
  * White blood cell (WBC) \> 3000 / mL
  * Absolute neutrophil count ≥ 1,500 / mcL
  * Platelets ≥ 100,000 / mcL
  * Creatinine ≤ 1.5x ULN
  * Estimated glomerular filtration rate (eGFR)\* \> 50 mL/min
  * Total bilirubin\*\* \< 2× ULN
  * Albumin \> 3 g/dL
  * Aspartate aminotransferase (AST) \< 3× ULN

    * \*based upon Chronic Kidney Disease- Epidemiology Collaboration (CKD-EPI) equation. Participants with estimated GFR between 50 - 60 mL/min will require a 99mTc-TPA GFR test and only participants with non-obstructive pathology will be included in the study.
    * \*\* Total bilirubin ≤ 2x ULN (except for participants with known Gilbert's Syndrome ≤ 3x ULN is permitted)
* International Prostate Symptoms Score (IPSS) ≤ 15.
* Medically fit for treatment and agreeable to follow-up.
* Ability to understand and the willingness to sign a written informed consent.
* Participants with partners of childbearing potential, agreement to use barrier contraceptive method (condom) and to continue its use for 14 weeks from receiving the last dose of Lu-PSMA-617. Participants must also not donate sperm for 14 weeks from receiving the last dose of Lu-PSMA-617.

Exclusion Criteria:

* Clinical or radiographic evidence of distant metastatic disease (M1a above aortic bifurcation, M1b, or M1c) by any imaging. Participants are allowed to M1a nodal disease that is below the aortic bifurcation. Negative PSMA PET/CT is an acceptable substitute to conventional staging.
* Prostate gland size \>90 cc measured by CT, ultrasound, or MRI
* Prior head and neck radiation therapy.
* Prior treatment for prostate cancer (incudes chemotherapy, radiation therapy, or anti-androgen therapy).
* Prohibited within 30 days prior to administration to study treatment: spironolactone and other investigational drug therapies.
* Prohibited 3 months before participant registration and during administration of study treatment: oral ketoconazole, , estrogens, and radiopharmaceuticals.
* History of prior pelvic radiation therapy.
* Enrollment concurrently in another investigational drug study within 6 months of registration.
* History of another active malignancy within the previous 3 years except for adequately treated skin cancer or superficial bladder cancer.
* History of prior myelodysplastic syndrome or acute leukemia.
* History of or active Crohn's disease or ulcerative colitis.
* Contraindication to or inability to tolerate PSMA/PET.
* Any condition that in the opinion of the investigator would preclude participation in this study.
* Inability to adhere to radiation safety measures in hospital or at home
* Prior treatment with radionuclide therapies, 177Lu-PSMA-617 or other
* Reduced salivary gland function with baseline CTCAE Gr \> 1 dry mouth will be excluded.

Where it's running

• University Hospitals Cleveland Medical Center Seidman Cancer Center, Case Comprehensive Cancer Center
  Cleveland, Ohio, United States Recruiting

Study contacts

• Principal investigator: Angela Y Jia, MD, PhD — University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
• Study coordinator: Angela Y Jia, MD, PhD
• Email: Angela.Jia@UHhospitals.org
• Phone: 216-844-3262

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted tumor boost and shortened radiation schedules for prostate cancer

  This trial tests whether giving a higher radiation dose to the tumor inside the prostate (a focal boost) and delivering treatment in 12 instead of 20 sessions helps men with intermediate- or high-risk prostate cancer have fewer relapses and need less hormonal therapy.

  Recruiting Copenhagen University Hospital, Rigshospitalet · Aarhus and 2 other locations · NCT07343349

• Improved robotic surgery for advanced prostate cancer

  This study tests a new robotic surgery technique for advanced prostate cancer to see if it helps improve recovery and urinary control compared to standard methods.

  Recruiting First Affiliated Hospital of Fujian Medical University · Fuzhou, Fujian · NCT06977906

• Genomic biomarker-guided therapy for advanced prostate cancer

  This study is testing if personalized treatment based on genetic markers can help men with advanced prostate cancer before surgery.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06387056

• Radiation therapy for metastatic prostate cancer treatment

  This study tests if adding a targeted radiation treatment to standard hormone therapy can help people with newly diagnosed metastatic prostate cancer have better control over their disease.

  Recruiting at 3 sites Phase 2 Case Comprehensive Cancer Center · New York, New York and 2 other locations · NCT06150417

• Combining relugolix and enzalutamide for high-risk prostate cancer treatment

  This study is testing if combining two medications, relugolix and enzalutamide, can help men with high-risk prostate cancer do better with their treatment and live longer.

  Recruiting Phase 1 University of Oklahoma · Oklahoma City, Oklahoma · NCT06130995

• Intense hormone therapy before surgery for advanced prostate cancer

  This study is testing whether a stronger hormone treatment before surgery can help men with advanced prostate cancer do better than the usual hormone therapy.

  Recruiting Phase 2 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Nanjing, Jiangsu · NCT05406999

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.